Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (SG:T14) has released an update.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, has successfully held its third board meeting for FY2024, where key resolutions were passed. The board approved the half-yearly financial statements prepared according to PRC accounting standards and International Financial Reporting Standards. Additionally, they endorsed the Report on the Deposit and Use of Proceeds, and adjustments to the Board’s committee compositions following an Independent Director’s retirement were made.
For further insights into SG:T14 stock, check out TipRanks’ Stock Analysis page.
